RefleXion is positioned to significantly improve the way cancer patients receive radiation treatment. The company’s first-of-its-kind technology, a biology-guided radiotherapy system (BgRT), is a revolutionary therapy that can deliver treatment with unprecedented precision. This technology, if successfully developed, could increase five-year survival rates for metastatic cancer patients. In addition, radiotherapy can often be limited by shortages of qualified radiotherapists, particularly in developing countries. RefleXion's technology holds the potential for significant automation, which could bring effective and accessible treatment to new markets.